# US 2012/0259002 A1 · Molecule for treating an inflammatory disorder

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0259002 A1
- Document ID: US20120259002A1
- Status: Published application
- Kind: A1
- Application number: 13/529,640
- Filed: 2012-06-21
- Published: 2012-10-11
- Earliest claimed: 2009-12-24
- Assignees: Acedemisch Ziekenhuis Leiden h.o.d.n. LUMC; Prosensa Technologies B.V.
- Inventors: Garrit-Jan Boudewijn Van Ommen; Annemieke Aartsma-Rus; Judith Christina Theodora Van Deutekom; Josephus Johannes De Kimpe; Joseph Stephan Verbeek; Aliye Seda Ylmaz-Elis
- Web page: https://patentgrep.com/patent/US20120259002A1

## CPC

- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- A61K 31/7115: Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
- A61K 31/712: Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 3/06: Antihyperlipidemics
- A61P 17/06: Antipsoriatics
- A61P 19/00: Drugs for skeletal disorders
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C12N 15/111: {General methods applicable to biologically active non-coding nucleic acids}
- C12N 15/1138: {against receptors or cell surface proteins}
- C12N 2310/11: Antisense
- C12N 2320/30: Special therapeutic applications
- C12N 2320/33: Alteration of splicing
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention provides two types of oligonucleotides for treating an inflammatory disorder: an oligonucleotide which is able of altering the splicing of a pre-mRNA encoding a C5 in order to decrease the amount of a C5a and an oligonucleotide which is able of altering the splicing of a pre-mRNA encoding a IL-1RAcP in order to increase the amount of a soluble IL-1RAcP. The invention further provides the use of said oligonucleotides for preventing or treating an inflammatory disorder.

## Claims

### Claim 1

An oligonucleotide which alters the splicing of a pre-mRNA encoding a IL-1RAcP in order to increase the amount of a soluble IL-1RacP or which alters the splicing of a pre-mRNA encoding a C5 in order to decrease the amount of a C5a.

### Claim 2 (depends on 1)

An oligonucleotide according to claim 1, wherein said oligonucleotide which alters the splicing of a pre-mRNA encoding a IL-1RAcP also induces the skipping of exon 9 of the pre-mRNA encoding a IL-1RacP, and/or wherein which alters the splicing of a pre-mRNA encoding a C5 also permits the amount of a C5b to remain unchanged.

### Claim 3 (depends on 2)

An oligonucleotide according to claim 2, wherein said oligonucleotide which alters the splicing of a pre-mRNA encoding a IL-1RacP also inhibits the inclusion of exon 9 of the pre-mRNA encoding IL-1RacP, and/or wherein said oligonucleotide which alters the splicing of a pre-mRNA encoding a C5 also is able to induce the skipping of exon 17 of the pre-mRNA encoding a C5.

### Claim 4 (depends on 1)

An oligonucleotide according to claim 1, wherein said oligonucleotide comprises a sequence which is complementary to or binds at least part of an exon of the C5 respectively IL-1RAcP pre-mRNA or at least part of a non-exon region of the C5 respectively IL-1RAcP pre-mRNA said part being a contiguous stretch comprising at least 8 nucleotides.

### Claim 5 (depends on 1)

An oligonucleotide according to claim 1, wherein said oligonucleotide comprises a sequence which is complementary to or binds a splice site or to an intronic sequence of a C5 respectively IL-1RAcP pre-mRNA.

### Claim 6 (depends on 4)

An oligonucleotide according to claim 4, wherein the contiguous stretch comprises 8-50 nucleotides, preferably 14-25 nucleotides, of RNA of an exon of the C5 respectively IL-1RAcP pre-mRNA.

### Claim 7 (depends on 4)

An oligonucleotide according to claim 4, wherein said oligonucleotide is complementary to or binds an exon of the C5 pre-mRNA represented by SEQ ID NO:1 or 2 and/or an exon of the IL-1RAcP represented by SEQ ID NO:3 or 4.

### Claim 8 (depends on 1)

An oligonucleotide according to claim 1, wherein said oligonucleotide comprises or consists of the following sequences: SEQ ID NO: 11-42.

### Claim 9 (depends on 1)

An oligonucleotide according to claim 1, wherein the oligonucleotide has a backbone, a sugar and/or a base modification compared to an RNA-based oligonucleotide, preferably wherein the oligonucleotide comprises or consists of one or more 2′-O-methyl phosphorothioate.

### Claim 10 (depends on 9)

An oligonucleotide according to claim 9, wherein the oligonucleotide comprises a 2′-O-methyl phosphorothioate oligoribonucleotide modification and a locked nucleic acid monomer.

### Claim 11 (depends on 1)

An oligonucleotide according to claim 1, wherein said oligonucleotide comprises at least one inosine and/or a base able to form a wobble base pair.

### Claim 12 (depends on 1)

A method for alleviating one or more symptom(s) and/or characteristic(s) and/or for improving a parameter of an inflammatory disorder in an individual, the method comprising administering to said individual an effective amount of an oligonucleotide according to claim 1 for preventing or treating an inflammatory disorder in an individual,

### Claim 13 (depends on 12)

The method of claim 12, wherein said disorder comprises rheumatoid arthritis (RA), juvenile rheumatoid arthritis, psoriasis, psoriatic arthritis, ankylosing spondylitis, inflammatory bowel disease including Crohn's disease or ulcerative colitis, hepatitis, sepsis, alcoholic liver disease, or non-alcoholic steatosis.

### Claim 14 (depends on 1)

A composition comprising an oligonucleotide of claim 1, wherein the composition is preferably a pharmaceutical composition said pharmaceutical composition comprising a pharmaceutically acceptable carrier, adjuvant, diluent and/or excipient.

### Claim 15 (depends on 14)

A composition according to claim 14, wherein at least a first and a second oligonucleotide are present in said composition, said first being an oligonucleotide which alters the splicing of a pre-mRNA encoding a IL-1RAcP in order to increase the amount of a soluble IL-1RacP and said second being an oligonucleotide which alters the splicing of a pre-mRNA encoding a C5 in order to decrease the amount of a C5a.
